Fisher said that it will closely collaborate with Carl Zeiss Jena, Cellomics' largest shareholder, in the high-content screening field. Cellomics had $13 million in revenues in 2004.
Fisher's revenues for the quarter increased 33 percent to $1.4 billion from $1 billion during the year-ago quarter. Excluding currency effects, organic revenues grew by 5.2 percent. Sales of scientific products and services accounted for 74 percent of total revenues this quarter.
The company did not break out its research and development expenses for the quarter.
The company had a net income this quarter of $101.4 million, or $.80 per share, more than double last year's $44.7 million, or $.64 per share, during the same period. This quarter's income included $16 million associated with discontinued operations, among them the sale of Atos Medical.
As of June 30, Fisher Scientific had $155.2 million in cash and cash equivalents.
Fisher also said it completed its acquisition of McKesson BioServices, a company managing biological specimens and clinical trial material, for $60 million on July 31.